15-lncRNA-Based Classifier-Clinicopathologic Nomogram Improves the Prediction of Recurrence in Patients with Hepatocellular Carcinoma

Table 1

Characteristics of the patients in the training set and validation set.

Variable	Category	Training set		Validation set
		()	%	()	%
Age (years)	Median	60		62
	Range(years)	18-82		25-90
	NA	0	0	0	0
Sex	Male	101	68.7	103	70.5
	NA	0	0	0	0
Race	Asian	69	46.9	63	43.2
	White	72	49.0	70	47.9
	Black or African American	4	2.7	8	5.5
	NA	2	1.4	5	3.4
Family history	Yes	44	29.9	45	30.8
	NA	22	15.0	18	12.3
HBV	Yes	49	33.3	44	30.1
	NA	7	4.8	7	4.8
HCV	Yes	19	12.9	23	15.8
	NA	7	4.8	7	4.8
Alcohol consumption	Yes	46	31.3	55	37.7
	NA	7	4.8	7	4.8
Mutation count	Median	79.5		83
	Range	12-1323		1-685
	NA	7	4.8	2	1.4
Fraction genome altered	Median	0.25		0.24
	Range	0-0.85	0	0-0.93
BMI	NA	3	2.0	2	1.4
	≤24	60	40.8
	>24	74	50.3
	NA	13	8.8
AFP (ng/mL)	≤20	59	40.1	71	48.6
	>20	59	40.1	42	28.8
	NA	29	19.7	33	22.6
Platelet (×109/L)	≤200	57	38.8	56	38.4
	>200	74	50.3	65	44.5
	NA	16	10.9	25	17.1
Albumin (g/dL)	≤4.0	62	42.2	60	41.1
	>4.0	63	42.9	61	41.8
	NA	22	15.0	25	17.1
Creatinine (mg/dL)	<1.1	100	68	91	62.3
	≥1.1	26	17.7	27	18.5
	NA	21	14.3	28	19.2
Liver cirrhosis	Yes	51	34.7	67	45.9
	NA	64	43.5	53	36.3
Histological grade	G1-G2	83	56.5	97	66.4
	G3-G4	62	42.2	47	32.2
	NA	2	1.4	2	1.4
T stage	T1-T2	105	71.4	115	78.8
	T3-T4	41	27.9	30	20.5
	NA	1	0.7	1	0.7
TNM stage	StageI-II	101	68.7	105	71.9
	StageIII-IV	39	26.5	30	20.5
	NA	7	4.8	11	7.5
ECOG	0	79	53.7	68	46.6
	>0	44	29.9	54	37.0
	NA	24	16.3	24	16.4

Abbreviations: NA: not available; AFP: alpha-fetoprotein.